Could a once-daily pill prevent heart transplant rejection better than the standard twice-daily regimen?
NCT ID NCT03373227
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study tested whether a once-daily anti-rejection medication (Envarsus) works as well as the standard twice-daily drug (Prograf) in heart transplant patients. Researchers looked at rates of organ rejection and graft failure, and whether taking the drug once a day helps patients stick to their treatment. The study involved 50 adult heart transplant recipients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLIANCE, PATIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.